Group items tagged

Product packaging affects the effectiveness of pharmaceuticals to a great extent. This is why pharmaceutical companies ensure they choose appropriate packaging for drug products. Drug packaging is not always an easy job. However, the tips in this article will help you select the proper pharmaceutical packaging for drug products without stress. What Does Pharmaceutical Packaging Entail? Pharmaceutical packaging involves using packaging containers with safety closures such as a lidding film to hold pharmaceutical products. This is done to keep them safe and effective. The most commonly used packaging materials in the pharmaceutical industry are metals, glass, and plastics. These materials are used for different reasons and different products. In short, a pharmacist considers several factors regarding a product and its target audience before choosing a packaging material for pharmaceutical formation. Why Appropriate Packaging Matters Many benefits come with appropriate pharmaceutical packaging. These benefits make it essential to package drug products in the best ways possible. When pharmaceutical items are properly packed, they can reach patients for a safe prescription. As a result, the drug stands a higher chance of achieving its prescription purpose. More so, properly packaged drug products are safer to consume and can be trusted.

The pharmaceutical industry is one of the most important and valuable industries in the world. It is responsible for developing and producing medicines that improve and save lives. However, there are some things you may not know about this fascinating industry. In this blog post, we will discuss six interesting facts about the pharmaceutical industry! 1. THE MANUFACTURING PROCESS OF PHARMACEUTICALS IS HIGHLY REGULATED All pharmaceutical products must go through a rigorous manufacturing process before they can be made available to patients. This process is heavily regulated by various government agencies to ensure that the medicines are safe and effective. The pharmaceutical manufacturing process usually involves multiple steps, including the preparation of raw materials, the manufacturing of active pharmaceutical ingredients (APIs), and the packaging and labeling of finished products. To ensure patient safety, all pharmaceutical companies must adhere to strict regulations set by government agencies such as the Food and Drug Administration (FDA). These regulations are designed to protect patients by ensuring that medicines are safe and effective.

Diaphragm pumps are positive displacement pumps that use a flexible diaphragm to displace a fluid volume. They're used to move fluids with viscous materials or solid particles because they can move the fluids without causing damage to the pump. Almost all major industries use diaphragm pumps to move concrete, acid, and abrasive fluids. Diaphragm pumps use power sources like air pressure, mechanical means, and electricity. One industry that relies heavily on diaphragm pump operation is the pharmaceutical industry. The diaphragm pump is suitable for the pharmaceutical industry because it can handle a variety of fluids and provide a gentle flow. This article discusses the various uses of diaphragm pumps in the pharmaceutical industry and how they have revolutionized it. 1. Filling Vials Filling vials with liquid medication is a task that has to be accurate and concise. Diaphragm pumps can dispense a precise amount of drugs into a vial. The pump provides an exact flow rate, ensuring each vial has the correct medication dosage. Diaphragm pumps reduce the risk of medication errors.

The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll. This trend appears to be persisting with the study showing a generally favourable view of the sector. The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians. The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field. Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.

As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges. As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology, big data, sustainability, ongoing policy changes and a shift in investment due to inflation. Utilising big data and tech Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare providers leveraging remote access further.

Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing. The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all urged policymakers to enable a more sustainable approach to prescribing. This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines procurement and improving the availability of data about the environmental impact of medicines. "We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement. They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.

Aspire Pharma has completed the acquisition of Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India); speciality generic pharmaceutical organisations. Morningside delivers Aspire added talent, increased in-market range, and an industry leading pipeline, complementary to Aspire's. "We are excited to welcome the Morningside team to the Aspire family. This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally," said Richard Condon, Chief Executive Officer of Aspire Pharma.

Sigma Pharmaceuticals, a leading pharmacy wholesaler and distributor in the UK, has once again demonstrated its commitment to supporting the local community by helping raise over £70,000 for local charitable causes. As per a statement from Watford-based industry leader, they raised £20,000 for Citizens Advice Watford, their selected charity of the year, during the recent Sigma annual conference held in Sun City, South Africa. Additionally, Sigma played a vital part in raising more than £52,000 for 'Team George' at the London Marathon Charity run held on Sunday, 21 April 2024 to support cancer charities. Throughout the year, Sigma will continue to partner with Citizens Advice Watford, a local charity that provides frontline service to the community, giving free, expert and impartial advice and support to 8,000 people a year, many of whom are facing crisis situations. Applauding the work done by this charity, Dr Bharat Shah CBE, Founder and Managing Director at Sigma, said: "It has been eye-opening to learn about the life-changing impact the charity has on the lives of so many people. "We have seen how their expert team works day in and day out to speak up for people who have nowhere else to turn, ensuring they receive the support and services they're entitled to."

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.

In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services. With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their target audience, and drive business growth. UNDERSTANDING THE UNIQUE LANDSCAPE The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs, and studying the competitive landscape are vital steps in developing an effective marketing plan. EMBRACING DIGITAL TRANSFORMATION Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized messaging, real-time communication, and targeted campaigns that resonate with the target audience.

AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company. In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations, and trading. Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

In many cases, a pharmacy's most valuable asset is its NHS contract. This is what buyers are paying for - the right to provide pharmaceutical services commissioned by the NHS and be reimbursed for the medicines dispensed. However, a pharmacy consists of more than just an NHS contract and when buyers look for a pharmacy to buy, they will also examine these other areas - the pharmacy's customer base, its staff, the property it operates from - to name a few - because these are all also crucial to a successful pharmacy. In this day and age, another important consideration is the pharmacy's intellectual property (IP) i.e. the pharmacy's rights to certain types of information, ideas, and forms of expression. At the most basic level, this includes the trade mark in the name of the pharmacy, because all pharmacies will have a name by which they distinguish themselves from other pharmacies. The more well-known the name, the more valuable this form of IP is - mention 'Boots', for example, and most will have an instant association with the largest pharmaceutical retailer in the UK.

Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier," said Laura Steele, president and general manager for Eli Lilly's Northern Europe division. ABPI said it was seeking early talks with the government to set out a new future settlement. In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.

Boehringer Ingelheim's UK & Ireland managing director Uday Bose has been elected chair of the European Medicines Group (EMG). Established in 2001, the EMG is a voice for UK operations of continental European headquartered research-based pharmaceutical companies and seeks to promote a dialogue between the UK Government, the NHS and wider stakeholders. "I am delighted to share the news that I have been elected chair," Bose wrote in a LinkedIn post, adding: "I look forward to working with the EMG to help support the ambition set out in the Life Sciences Vision for the UK to be a world leader in life sciences." Bose is a vastly experienced pharmaceutical industry leader who has had over 20 years' experience spanning general management, health economics, sales and marketing roles with national, regional and global accountability.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."